Stock comparison
Harmony Biosciences Holdings
ImmunityBio
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
IBRX
ImmunityBio
Market cap
$7.56B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HRMY | IBRX | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 31F | HRMY |
| Benjamin Graham | 60C | 45D | HRMY |
| Philip Fisher | 75B | 53C | HRMY |
| Peter Lynch | 62C | 52C | HRMY |
| Joel Greenblatt | 28F | 2F | HRMY |
| Charlie Munger | 62C | 53D | HRMY |
| Terry Smith | 67B | 55C | HRMY |
Side-by-side metrics
| Metric | HRMY | IBRX |
|---|---|---|
| Market cap | $1.75B | $7.56B |
| P/E (TTM) | 11.8x | - |
| EV/EBIT | 6.4x | - |
| ROIC (TTM) | 12.5% | -44.51% |
| Gross margin | 76.55% | 93.79% |
| Net margin | 16.2% | -6.06% |
| Revenue CAGR 5y | 29.85% | 2.32% |
| EPS CAGR 5y | 46.45% | - |
| Debt / Equity | 0.2x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HRMY leads on
- ROIC (TTM)12.5%vs -44.51%+128%
- Net margin16.2%vs -6.06%+103%
IBRX leads on
- P/E (TTM)-vs 11.8x+175%
- EV/EBIT-vs 6.4x+119%
- Debt / Equity-vs 0.2x+118%
- Revenue CAGR 5y2.32%vs 29.85%+87%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.